NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Humphrey L, Chan BKS, Detlefsen S, et al. Screening for Breast Cancer [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2002 Aug. (Systematic Evidence Reviews, No. 15.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Screening for Breast Cancer

Screening for Breast Cancer [Internet].

Show details

References

1.
American Cancer Society. Cancer facts and figures, 2002. Available at: http://www​.cancer.org​/downloads/STT/F&F2001.pdf..
2.
Seidman H, Stellman S D, Mushinski M H. A different persepctive on breast cancer risk factors: Some implications of the nonattributable risk. Cancer. 1982;32:301–312. [PubMed: 6811109]
3.
Strax P. Mass screening of asymptomatic women. In: Ariel IM, Cleary J, eds. Breast cancer: Diagnosis and treatment. New York: McGraw-Hill; 1987:145–151.
4.
Gail M, Brinton L A, Byar D P. et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879–1886. [PubMed: 2593165]
5.
Colditz GA, Willett WC, Hunter DJ, et al. Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study [published erratum appears in JAMA 1993 Oct 6;270(13):1548]. JAMA. 1993:270(3):338–343. [PubMed: 8123079]
6.
Chu K C, Tarone R E, Bessler L G. et al. Recent trends in US breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst. 1996;88:1571–1579. [PubMed: 8901855]
7.
Tarone R E, Chu K C, Gaudette L A. Birth cohort and calendar period trends in breast cancer mortality in the United States and Canada. J Natl Cancer Inst. 1997;89:251–256. [PubMed: 9017006]
8.
Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% at ages 20–69 years. Lancet. 2000;355:1822. [PubMed: 10832853]
9.
US Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore: Williams & Wilkins; 1996.
10.
Skrabanek P. False premises and false promises of breast cancer screening. Lancet. 1985(August 10):316–320. [PubMed: 2862479]
11.
Ringash J. Canadian Task Force on Preventive Health Care. Preventive health care, 2001 update: screening mammography among women aged 40–49 years at average risk of breast cancer. Can Med Assoc J. 2001;164(4):469–476. [PMC free article: PMC80774] [PubMed: 11233866]
12.
Tabar L, Vitak B, Chen H H T, Yen M F, Duffy S W, Smith R A. Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality. Cancer. 2001;91(9):1724–1731. [PubMed: 11335897]
13.
Gotzsche PC, Olsen O. Review: High quality studies do not show reductions in breast cancer mortality for women screened with mammography. ACP J Club. 2000:67.
14.
Rajkumar S V, Hartmann L C. Screening mammography in women aged 40–49 years. Medicine. 1999;78(6):410–416. [PubMed: 10575423]
15.
Glasziou P, Irwig L. The quality and interpretation of mammographic screening trials for women ages 40–49. J Natl Cancer Inst Monogr. 1997(22):73–77. [PubMed: 9709280]
16.
Kerlikowske K, Grady D, Rubin S M, Sandrock C, Ernster V L. Efficacy of screening mammography. A meta-analysis. JAMA. 1995;273(2):149–154. [PubMed: 7799496]
17.
Nystrom L, Rutqvist LE, Wall S et al. Breast cancer screening with mammography: overview of Swedish randomised trials [published erratum appears in Lancet 1993 Nov 27;342(8883):1372]. Lancet. 1993:341(8851):973–978. [PubMed: 8096941]
18.
Smart CR, Hendrick RE, Rutledge JH, 3rd, Smith RA. Benefit of mammography screening in women ages 40 to 49 years. Current evidence from randomized controlled trials [published erratum appears in Cancer 1995 Jun 1;75(11):]. Cancer. 1995; 75(7):1619–1626. [PubMed: 8826919]
19.
Shapiro S. Is meta-analysis a valid approach to the evaluation of small effects in observational studies? J Clin Epidemiol. 1997;50(3):223–229. [PubMed: 9120519]
20.
Larsson LG, Andersson I, Bjurstam N, et al. Updated overview of the Swedish Randomized Trials on Breast Cancer Screening with Mammography: age group 40–49 at randomization. J Natl Cancer Inst Monogr. 1997:57–61. [PubMed: 9709277]
21.
Larsson L G, Nystrom L, Wall S. et al. The Swedish randomised mammography screening trials: analysis of their effect on the breast cancer related excess mortality. J Med Screen. 1996;3(3):129–132. [PubMed: 8946307]
22.
Hendrick RE, Smith RA, Rutledge JH, 3rd, Smart CR. Benefit of screening mammography in women aged 40–49: a new meta-analysis of randomized controlled trials. J Natl Cancer Inst Monogr. 1997(22):87–92. [PubMed: 9709282]
23.
Sirovich B E, Sox H C Jr. Breast cancer screening. Surg Clin North Am. 1999;79(5):961–990. [PubMed: 10572546]
24.
Olsen O, Gotzsche P C. Cochrane review on screening for breast cancer with mammography. Lancet. 2001;358(9290):1340–1342. [PubMed: 11684218]
25.
Moss S. A trial to study the effect on breast cancer mortality of annual mammographic screening in women starting at age 40. Trial Steering Group. J Med Screen. 1999;6:144–148. [PubMed: 10572845]
26.
Ng EH, Ng FC, Tan PH, et al. Results of intermediate measures from a population-based, randomized trial of mammographic screening prevalence and detection of breast carcinoma among Asian women: the Singapore Breast Screening Project [published erratum appears in Cancer 1998 Jul 1;83(1):191]. Cancer. 1998;82:1521–1528. [PubMed: 9554530]
27.
Hakama M P E H M, Kallio M. Effectiveness of the public health policy for breast cancer screening in Finland: population based cohort study. BMJ. 1997;314:864–867. [PMC free article: PMC2126259] [PubMed: 9093096]
28.
Hakama M, Pukkala E, Söderman B, Day N. Implementation of screening as a public health policy: issues in design and evaluation. J Med Screen. 1999;6:209–216. [PubMed: 10693068]
29.
Berglund G, Nilsson P, Eriksson K F. et al. Long-term outcome of the Malmo preventive project: mortality and cardiovascular morbidity. J Intern Med. 2000;247(1):19–29. [PubMed: 10672127]
30.
Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist L E. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet. 2002;359:909–919. [PubMed: 11918907]
31.
Cox B. Variation in the effectiveness of breast screening by year of follow-up. J Natl Cancer Inst Monogr. 1997(22):69–72. [PubMed: 9709279]
32.
Elwood JM, Cox B, Richardson AK. The effectiveness of breast cancer screening by mammography in younger women. Online J Curr Clin Trials. 1993;Doc(32):[23,227 words; 195 paragraphs]. [PubMed: 8305999]
33.
Kerlikowske K. Efficacy of screening mammography among women aged 40 to 49 years and 50 to 69 years: comparison of relative and absolute benefit. J Natl Cancer Inst Monogr. 1997(22):79–86. [PubMed: 9709281]
34.
Berry D A. Benefits and risks of screening mammography for women in their forties: a statistical appraisal. Journal of the National Cancer Institute. 1998;90(19):1431–1439. [PubMed: 9776408]
35.
Fletcher S, Black W, Harris R, Rimer B K, Shapiro S. Report of the International Workshop on Screening for Breast Cancer. Journal of the National Cancer Institute. 1993;85:1644–1656. [PubMed: 8105098]
36.
Mushlin A I, Kouides R W, Shapiro D E. Estimating the accuracy of screening mammography: a meta-analysis. Am J Prev Med. 1998;14(2):143–153. [PubMed: 9631167]
37.
Shen Y, Zelen M. Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations. J Clin Oncol. 2001;19(15):3490–3499. [PubMed: 11481355]
38.
Verbeek A L, Hendriks J H, Holland R, Mravunac M, Sturmans F, Day N E. Reduction of breast cancer mortality through mass screening with modern mammography. First results of the Nijmegen project, 1975-1981. Lancet. 1984;1:1222–1224. [PubMed: 6144933]
39.
Chamberlain J, Coleman D, Ellman R, Moss S. Verification of the cause of death in the trial of early detection of breast cancer. UK Trial of Early Detection of Breast Cancer Group. Trial Co-ordinating Centre. Br J Cancer. 1991;64(6):1151–1156. [PMC free article: PMC1977852] [PubMed: 1764379]
40.
Collette H J, de Waard F, Rombach J J, Collette C, Day N E. Further evidence of benefits of a (non-randomised) breast cancer screening programme: the DOM project. J Epidemiol Community Health. 1992;46(4):382–386. [PMC free article: PMC1059605] [PubMed: 1431712]
41.
Semiglazov V F, Moiseenko V M, Manikhas A G. et al. [Interim results of a prospective randomized study of self-examination for early detection of breast cancer (Russia/St.Petersburg/WHO)] The role of breast self-examination in early breast cancer detection (results of the 5-years USSR/WHO randomized study in Leningrad) Vopr Onkol. 1999;45(3):265–271. [PubMed: 10443229]
42.
Thomas D B, Gao D L, Self S G. et al. Randomized trial of breast self-examination in Shanghai: methodology and preliminary results. Journal of the National Cancer Institute. 1997;89(5):355–365. [PubMed: 9060957]
43.
Richert-Boe K E, Humphrey L L. Screening for cancers of the cervix and breast. Arch Intern Med. 1992;152(12):2405–2411. [PubMed: 1456849]
44.
Anonymous. 16-year mortality from breast cancer in the UK Trial of Early Detection of Breast Cancer. Lancet. 1999;353(9168):1909–1914. [PubMed: 10371568]
45.
Harris R P, Helfand M, Woolf S H. et al. Methods of the third U.S. Preventive Services Task Force. Am J Prev Med. 2001;20(3S):21–35. [PubMed: 11306229]
46.
Moher D, Pham B, Jones A. et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? [see comments.] Lancet. 1998;352(9128):609–613. [PubMed: 9746022]
47.
Schulz K F, Chalmers I, Hayes R J, Altman D G. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273(5):408–412. [PubMed: 7823387]
48.
Prorok P C, Hankey B F, Bundy B N. Concepts and problems in the evaluation of screening programs. J Chronic Dis. 1981;34:159–171. [PubMed: 7014584]
49.
Schulz K F, Grimes D A, Altman D G, Hayes R J. Blinding and exclusions after allocation in randomized controlled trials: survey of published parallel group trials in obstetrics and gynecology. BMJ. 1996;312:742–744. [PMC free article: PMC2350472] [PubMed: 8605459]
50.
Johansen H K, Gotzsche P C. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA. 1999;282(18):1752–1759. [PubMed: 10568648]
51.
Bailar J C. Mammography: a contrary view. Ann Intern Med. 1976;84:77–84. [PubMed: 1106292]
52.
Skrabanek P. Mass mammography. The time for reappraisal. Int J Technol Assess Health Care. 1989;5(3):423–430. [PubMed: 10303911]
53.
Schmidt J G. The epidemiology of mass breast cancer screening--a plea for a valid measure of benefit. J Clin Epidemiol. 1990;43:215–225. [PubMed: 2107280]
54.
Glasziou P P, Woodward A J, Mahon C M. Mammographic screening trials for women aged under 50. A quality assessment and meta-analysis. Med J Aust. 1995;162(12):625–629. [PubMed: 7603372]
55.
Tarone R. The excess of patients with advanced breast cancer in young women screened with mammography in the Canadian National Breast Screening Study. Cancer. 1995;75:997–1003. [PubMed: 7842421]
56.
Miller A B, To T, Baines C J, Wall C. The Canadian National Breast Cancer Screening Study - I, breast cancer mortality after 11 to 16 years of follow-up in women age 40 to 49. Ann Intern Med. 2002;137:305–12. [PubMed: 12204013]
57.
WinBUGS Version 1.2 User Manual [computer program]. Version. Cambridge, England: MRC Biostatistics Unit; 1999.
58.
Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years [published erratum appears in CMAJ 1993 Mar 1;148(5):718]. Can Med Assoc J. 1992;147:1477–1488. [PMC free article: PMC1336544] [PubMed: 1423088]
59.
Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years [published erratum appears in CMAJ 1993 Mar 1;148(5):718]. Can Med Assoc J. 1992;147:1459–1476. [PMC free article: PMC1336543] [PubMed: 1423087]
60.
Sutton AJ, Abams KR, Jones DR, Sheldon TA, Song F. Methods for Meta-analysis in Medical Research. Chichester: John Wiley and Sons, Ltd.; 2000.
61.
Van Dijck J A, Verbeek A L, Beex L V. et al. Mammographic screening after the age of 65 years: evidence for a reduction in breast cancer mortality. Int J Cancer. 1996;66(6):727–731. [PubMed: 8647640]
62.
Laya M B, Larson E B, Taplin S H, White E. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. Journal of the National Cancer Institute. 1996;88(10):643–649. [PubMed: 8627640]
63.
Greendale G A, Reboussin B A, Sie A. et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med. 1999;130:262–269. [PubMed: 10068383]
64.
Marugg R C, van der Mooren M J, Hendriks J H, Rolland R, Ruijs S H. Mammographic changes in postmenopausal women on hormonal replacement therapy. Eur Radiol. 1997;7(5):749–755. [PubMed: 9166577]
65.
Kerlikowske K, Grady D, Barclay J, Sickles E A, Ernster V. Effect of age, breast density, and family history on the sensitivity of first screening mammography. JAMA. 1996;276(1):33–38. [PubMed: 8667536]
66.
Eddy D. Screening for breast cancer. Ann-Intern-Med. 1989;111:389–399. [PubMed: 2504094]
67.
Lidbrink E, Elfving J, Frisell J, Jonsson E. Neglected aspects of false positive findings of mammography in breast cancer screening: analysis of false positive cases from the Stockholm trial. BMJ. 1996;312(7026):273–276. [PMC free article: PMC2349888] [PubMed: 8611781]
68.
Sickles EA. Breast cancer screening outcomes in women ages 40–49: clinical experience with service screening using modern mammography. J Natl Cancer Inst Monogr. 1997(22):99–104. [PubMed: 9709284]
69.
Hunt K A, Rosen E L, Sickles E A. Outcome analysis for women undergoing annual versus biennial screening mammography: a review of 24,211 examinations. AJR Am J Roentgenol. 1999;173(2):285–289. [PubMed: 10430120]
70.
Wald N J, Murphy P, Major P, Parkes C, Townsend J, Frost C. UKCCCR multicentre randomised controlled trial of one and two view mammography in breast cancer screening. BMJ. 1995;311:1189–1193. [PMC free article: PMC2551114] [PubMed: 7488893]
71.
Bassett L W, Shayestehfar B, Hirbawi I. Obtaining previous mammograms for comparison: usefulness and costs. AJR Am J Roentgenol. 1994;163(5):1083–1086. [PubMed: 7976879]
72.
Warren R M, Duffy S W, Bashir S. The value of the second view in screening mammography. Br J Radiol. 1996;69:105–108. [PubMed: 8785635]
73.
Young K C, Wallis M G, Blanks R G, Moss S M. Influence of number of views and mammographic film density on the detection of invasive cancers: results from the NHS Breast Screening Programme. Br J Radiol. 1997;70(833):482–488. [PubMed: 9227229]
74.
Sickles E A. Findings at mammographic screening on only one standard projection: outcomes analysis. Radiology. 1998;208(5):471–475. [PubMed: 9680578]
75.
Elmore J G, Barton M B, Moceri V M, Polk S, Arena P J, Fletcher S W. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med. 1998;338(16):1089–1096. [PubMed: 9545356]
76.
Christiansen C L, Wang F, Barton M B. et al. Predicting the cumulative risk of false-positive mammograms. Journal of the National Cancer Institute. 2000;92(20):1657–1666. [PubMed: 11036111]
77.
Kerlikowske K, Grady D, Barclay J, Sickles E A, Eaton A, Ernster V. Positive predictive value of screening mammography by age and family history of breast cancer. JAMA. 1993;270(20):2444–2450. [PubMed: 8230621]
78.
Kerlikowske K, Grady D, Barclay J, Sickles E A, Ernster V. Likelihood ratios for modern screening mammography. Risk of breast cancer based on age and mammographic interpretation. JAMA. 1996;276(1):39–43. [PubMed: 8667537]
79.
Harris R. Breast cancer among women in their forties: toward a reasonable research agenda [editorial] Journal of the National Cancer Institute. 1994;86(6):410–412. [PubMed: 8120910]
80.
Peer P G, van Dijck J A, Hendriks J H, Holland R, Verbeek A L. Age-dependent growth rate of primary breast cancer. Cancer. 1993;71(11):3547–3551. [PubMed: 8490903]
81.
Chen H H, Tabar L, Fagerberg G, Duffy S W. Effect of breast cancer screening after age 65. J Med Screen. 1995;2:10–14. [PubMed: 7497137]
82.
Frisell J, Lidbrink E. The Stockholm Mammographic Screening Trial: Risks and benefits in age group 40–49 years. J Natl Cancer Inst Monogr. 1997;22:49–51. [PubMed: 9709275]
83.
Kerlikowske K, Phillips K A, Cummings S R, Salzmann P, Cauley J A. Screening mammography in elderly women. JAMA. 2000;283(24):3202–3204. [PubMed: 10866866]
84.
Sala E, Warren R, McCann J, Duffy S, Day N, Luben R. Mammographic parenchymal patterns and mode of detection: implications for the breast screening programme. J Med Screen. 1998;5(4):207–212. [PubMed: 9934652]
85.
Mandelson M T, Oestreicher N, Porter P L. et al. Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. Journal of the National Cancer Institute. 2000;92(13):1081–1087. [PubMed: 10880551]
86.
Costanza M. Breast cancer screening in older women: overview. J Gerontol. 1992;47(Sp.13):1–16. [PubMed: 1430870]
87.
Goergen S K E J C G P, MacMillan J H. Characteristics of breast carcinomas missed by screening radiologists. Radiology. 1997;204:131–135. [PubMed: 9205234]
88.
Tabar L, Fagerberg G, Chen H H, Duffy S W, Gad A. Screening for breast cancer in women aged under 50: mode of detection, incidence, fatality, and histology. J Med Screen. 1995;2:94–98. [PubMed: 7497163]
89.
Rosenberg R, Hunt W, Williamson M. Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitvity and cancer stage at diagnosis: review of 183, 134 screening mammograms in Albuquerque, New Mexico. Radiology. 1998;209(2):511–518. [PubMed: 9807581]
90.
Baines C J, Vidmar M, McKeown-Eyssen G, Tibshirani R. Impact of menstrual phase on false-negative mammograms in the Canadian National Breast Screening Study. Cancer. 1997;80:720–724. [PubMed: 9264355]
91.
Burrell H C, Sibbering D M, Wilson A R. et al. Screening interval breast cancers: mammographic features and prognosis factors. Radiology. 1996;199(3):811–817. [PubMed: 8638010]
92.
Kerlikowske K, Carney P A, Geller B. et al. Performance of screening mammography among women with and without a first-degree relative with breast cancer. Ann Intern Med. 2000;133(11):855–863. [PubMed: 11103055]
93.
Barton M B, Harris R, Fletcher S W. Does this patient have breast cancer? The screening clinical breast examination: should it be done? How? JAMA. 1999;282(13):1270–1280. [PubMed: 10517431]
94.
Bobo J K, Lee N C, Thames S F. Findings from 752,081 clinical breast examinations reported to a national screening program from 1995 through 1998. Journal of the National Cancer Institute. 2000;92(12):971–976. [PubMed: 10861308]
95.
Baines C J. The Canadian National Breast Screening Study: responses to controversy. Womens Health Issues. 1992;2(4):206–211. [PubMed: 1486284]
96.
Baines CJ, Miller AB. Mammography versus clinical examination of the breasts. J Natl Cancer Inst Monogr. 1997(22):125–129. [PubMed: 9709288]
97.
Shapiro S, Venet W, Strax P, Venet L, Roeser R. Ten- to fourteen-year effect of screening on breast cancer mortality. Journal of the National Cancer Institute. 1982;69:349–355. [PubMed: 6955542]
98.
O'Malley M S, Fletcher S W. US Preventive Services Task Force. Screening for breast cancer with breast self-examination. A critical review. JAMA. 1987;257(16):2196–2203. [PubMed: 3550165]
99.
Fletcher S W, O'Malley M S, Earp J L, Morgan T M, Lin S, Degnan D. How best to teach women breast self-examination. A randomized controlled trial. Ann Intern Med. 1990;112(10):772–779. [PubMed: 2184711]
100.
Newcomb P A, Weiss N S, Storer B E, Scholes D, Young B E, Voigt L F. Breast self-examination in relation to the occurrence of advanced breast cancer. Journal of the National Cancer Institute. 1991;83(4):260–265. [PubMed: 1994055]
101.
Bjurstam N, Bjorneld L, Duffy S W. et al. The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39–49 years at randomization. Cancer. 1997;80(11):2091–2099. [PubMed: 9392331]
102.
Bjurstam N, Bjorneld L, Duffy S W. et al. The Gothenburg Breast Cancer Screening Trial: preliminary results on breast cancer mortality for women aged 39–49 [letter] J Natl Cancer Inst Monogr. 1997;22:53–55. [PubMed: 9709276]
103.
Andersson I, Janzon L. Reduced breast cancer mortality in women under age 50: updated results from the Malmo Mammographic Screening Program. J Natl Cancer Inst Monogr. 1997;22:63–67. [PubMed: 9709278]
104.
Tabar L, Fagerberg G, Chen H H. et al. Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial. Cancer. 1995;75:2507–2517. [PubMed: 7736395]
105.
Frisell J, Lidbrink E, Hellstrom L, Rutqvist L E. Followup after 11 years--update of mortality results in the Stockholm mammographic screening trial. Breast Cancer Research & Treatment. 1997;45:263–270. [PubMed: 9386870]
106.
Alexander F E, Anderson T J, Brown H K. et al. 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening. Lancet. 1999;353(9168):1903–1908. [PubMed: 10371567]
107.
Shapiro S, Venet W, Strax P, Venet L. Current results of the breast cancer screening randomized trial: The health insurance plan (HIP) of greater New York study. In: Day NE, Miller AB, eds. Screening for Breast Cancer. Toronto: Hans Huber; 1988:3–15.
108.
Miller A B, To T, Baines C J, Wall C. The Canadian National Breast Cancer Screening Study-2: 13-year results of a randomized trial in women aged 50–59 years. J Natl Cancer Inst. 2000;92(18):1490–1499. [PubMed: 10995804]
109.
Miller A B, To T, Baines C J, Wall C. The Canadian National Breast Screening Study: update on breast cancer mortality. J Natl Cancer Inst Monogr. 1997;22:37–41. [PubMed: 9709273]
110.
Nystrom L. How effective is screening for breast cancer? [letter; comment] BMJ. 2000;321(7262):647–648. [PMC free article: PMC1118537] [PubMed: 10987748]
111.
Andersson I, Aspegren K, Janzon L. et al. Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. BMJ. 1988;297:943–948. [PMC free article: PMC1834636] [PubMed: 3142562]
112.
Tabar L, Vitak B, Chen H H. et al. The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiol Clin North Am. 2000;38(4):625–651. [PubMed: 10943268]
113.
Shapiro S. Periodic screening for breast cancer: the HIP Randomized Controlled Trial. Health Insurance Plan. J Natl Cancer Inst Monogr. 1997;22:27–30. [PubMed: 9709271]
114.
Tabar L, Fagerberg G, Duffy S W, Day N E. The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit. J Epidemiol Community Health. 1989;43:107–114. [PMC free article: PMC1052811] [PubMed: 2512366]
115.
Black W C, Haggstrom D A, Welch H G. All-cause mortality in randomized trials of cancer screening. Journal of the National Cancer Institute. 2002;94(3):167–173. [PubMed: 11830606]
116.
Sjonell G, Stahle L. Scientific foundation of mammographic screening is based on inconclusive research in Sweden. BMJ. 1999;319(7201):55. [PMC free article: PMC1116156] [PubMed: 10390473]
117.
Nystrom L, Larsson L G, Wall S. et al. An overview of the Swedish randomised mammography trials: total mortality pattern and the representivity of the study cohorts. J Med Screen. 1996;3:85–87. [PubMed: 8849766]
118.
Tabar L, Gad A, Holmberg L, Ljungquist U. Significant reduction in advanced breast cancer. Results of the first seven years of mammography screening in Kopparberg, Sweden. Diagnostic Imaging in Clinical Medicine. 1985;54:158–164. [PubMed: 3896614]
119.
Tabar L, Fagerberg CJ, Gad A, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet. 1985;1. [PubMed: 2858707]
120.
Shapiro S. Evidence on screening for breast cancer from a randomized trial. Cancer-(Philadelphia) 1977;39:2772–2782. [PubMed: 326378]
121.
Baines C J. Screening for breast cancer: how useful are clinical breast examinations? Journal of the National Cancer Institute. 2000;92(12):958–959. [PubMed: 10861299]
122.
Fletcher SW. Breast cancer screening among women in their forties: an overview of the issues. J Natl Cancer Inst Monogr. 1997(22):5–9. [PubMed: 9709267]
123.
Feuer E, Wun L, Boring C, Flanders W, MJ T, T.T. The lifetime risk of developing breast cancer. J Natl Cancer Inst. 1993;85:892–897. [PubMed: 8492317]
124.
Phillips K A, Glendon G, Knight J. Putting the risk of breast cancer in perspective. N Engl J Med. 1999;340:141–144. [PubMed: 9887168]
125.
Kopans D B. Updated results of the trials of screening mammography. Surg Oncol Clin N Am. 1997;6(2):233–263. [PubMed: 9115494]
126.
Antman K, Shea S. Screening mammography under age 50. JAMA. 1999;281(16):1470–1472. [PubMed: 10227298]
127.
Duffy S W, Chen H H, Tabar L, Fagerberg G, Paci E. Sojourn time, sensitivity and positive predictive value of mammography screening for breast cancer in women aged 40–49. Int J Epidemiol. 1996;25:1139–1145. [PubMed: 9027517]
128.
Tabar L, Vitak B, Chen H H, Prevost T C, Duffy S W. Update of the Swedish Two-County Trial of breast cancer screening: histologic grade-specific and age-specific results. Swiss Surg. 1999;5(5):199–204. [PubMed: 10546517]
129.
Tabar L, Chen H H, Fagerberg G, Duffy S W, Smith T C. Recent results from the Swedish Two-County Trial: the effects of age, histologic type, and mode of detection on the efficacy of breast cancer screening. J Natl Cancer Inst Monogr. 1997;22:43–47. [PubMed: 9709274]
130.
Tabar L, Faberberg G, Day N E, Holmberg L. What is the optimum interval between mammographic screening examinations? An analysis based on the latest results of the Swedish two- county breast cancer screening trial. Br J Cancer. 1987;55:547–551. [PMC free article: PMC2001715] [PubMed: 3606947]
131.
Duffy S W, Day N E, Tabar L, Chen H H, Smith T C. Markov models of breast tumor progression: some age-specific results. J Natl Cancer Inst Monogr. 1997;22:93–97. [PubMed: 9709283]
132.
Kopans DB. An overview of the breast cancer screening controversy. J Natl Cancer Inst Monogr. 1997(22):1–3. [PubMed: 9709266]
133.
Baines C J. The Canadian National Breast Screening Study: a perspective on criticisms. Ann Intern Med. 1994;120:326–334. [PubMed: 8291826]
134.
Cohen M M, Kaufert P A, MacWilliam L, Tate R B. Using an alternative data source to examine randomization in the Canadian National Breast Screening Study. J Clin Epidemiol. 1996;49(9):1039–1044. [PubMed: 8780614]
135.
Baines C J. A different view on what is known about breast screening and the Canadian National Breast Screening Study. Cancer. 1994;74(4):1207–1211. [PubMed: 8055439]
136.
Boyd N F. The review of randomization in the Canadian National Breast Screening Study. Is the debate over? [editorial; comment] Can Med Assoc J. 1997;156(2):207–209. [PMC free article: PMC1226910] [PubMed: 9012723]
137.
Bailar J C 3rd, MacMahon B. Randomization in the Canadian National Breast Screening Study: a review for evidence of subversion. Can Med Assoc J. 1997;156(2):193–199. [PMC free article: PMC1226907] [PubMed: 9012720]
138.
Narod S A. On being the right size: a reappraisal of mammography trials in Canada and Sweden [letter] Lancet. 1997;349(9068):1846. [PubMed: 9269247]
139.
Chu K C, Smart C R, Tarone R E. Analysis of breast cancer mortality and stage distribution by age for the Health Insurance Plan clinical trial. Journal of the National Cancer Institute. 1988;80:1125–1132. [PubMed: 3411625]
140.
Glasziou P P. Meta-analysis adjusting for compliance: the example of screening for breast cancer. J Clin Epidemiol. 1992;45(11):1251–1256. [PubMed: 1432006]
141.
Kerlikowske K, Grady D, Ernster V. Benefit of mammography screening in women ages 40–49 years: current evidence from randomized controlled trials [letter] Cancer. 1995;76(9):1679–1681. [PubMed: 8635076]
142.
Wilson T E, Helvie M A, August D A. Breast cancer in the elderly patient: early detection with mammography. Radiology. 1994;190(1):203–207. [PubMed: 8259405]
143.
Holmes F F, Hearne E 3rd. Cancer stage-to-age relationship: implication for cancer screening in the elderly. J Am Geriat Soc. 1981;29:55–57. [PubMed: 7462542]
144.
Brown J T, Hulka B S. Screening mammography in the elderly: a case control study. J Gen Intern Med. 1988;3(Mar/Apr):126–131. [PubMed: 3357069]
145.
Van Dijck J A, Verbeek A L, Beex L V. et al. Breast-cancer mortality in a non-randomized trial on mammographic screening in women over age 65. Int J Cancer. 1997;70(2):164–168. [PubMed: 9009155]
146.
Smith-Bindman R, Kerlikowske K, Gebretsadik T, Newman J. Is screening mammography effective in elderly women? Am J Med. 2000;108(2):112–119. [PubMed: 11126304]
147.
Walter L C, Covinsky K E. Cancer screening in elderly patients: a framework for individualized decision making. JAMA. 2001;285:2750–2756. [PubMed: 11386931]
148.
Satariano W A, Ragland D R. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994;120(2):104–110. [PubMed: 8256968]
149.
Mandelblatt J S, Wheat M E, Monane M, Moshief R D, Hollenberg J P, Tang J. Breast cancer screening for elderly women with and without comorbid conditions. A decision analysis model. Ann Intern Med. 1992;116(9):722–730. [PubMed: 1558343]
150.
Kerlikowske K, Salzmann P, Phillips K A, Cauley J A, Cummings S R. Continuing screening mammography in women aged 70 to 79 years: impact on life expectancy and cost-effectiveness. JAMA. 1999;282(22):2156–2163. [PubMed: 10591338]
151.
Semiglazov V F, Moiseyenko V M, Bavli J L. et al. The role of breast self-examination in early breast cancer detection (results of the 5-years USSR/WHO randomized study in Leningrad) Eur J Epidemiol. 1992;8(4):498–502. [PubMed: 1397215]
152.
Holmberg L, Ekbom A, Calle E, Mokdad A, Byers T. Breast cancer mortality in relation to self-reported use of breast self-examination. A cohort study of 450,000 women. Breast Cancer Res Treat. 1997;43(2):137–140. [PubMed: 9131269]
153.
Harvey B J, Miller A B, Baines C J, Corey P N. Effect of breast self-examination techniques on the risk of death from breast cancer. Can Med Assoc J. 1997;157(9):1205–1212. [PMC free article: PMC1228347] [PubMed: 9361639]
154.
Rimer BK, Bluman LG. The psychosocial consequences of mammography. J Natl Cancer Inst Monogr. 1997(22):131–138. [PubMed: 9709289]
155.
Harris R. Variation of benefits and harms of breast cancer screening with age. J Natl Cancer Inst Monogr. 1997(22):139–143. [PubMed: 9709290]
156.
Fonesca R, Hartmann L C, Petersen I, Donohue J H, Crotty T, Givsold J J. Ductal carcinoma in situ of the breast. Ann Intern Med. 1997;127(11):1013–1022. [PubMed: 9412283]
157.
Welch H G, Black W C. Using autopsy series to estimate the disease “reservoir” for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med. 1997;127(11):1023–1028. [PubMed: 9412284]
158.
Page D L, Jensen R A. Ductal carcinoma in situ of the breast: understanding the misunderstood stepchild. JAMA. 1996;275(12):948–949. [PubMed: 8598624]
159.
Swartz H M, Reichling B A. The risks of mammograms. JAMA. 1977;237(10):965–966. [PubMed: 576249]
160.
Silverstein M J. Noninvasive breast cancer. The dilemma of the 1990s. Obstetrics & Gynecology Clinics of North America. 1994;21(4):639–658. [PubMed: 7731639]
161.
Harstall C. Mammography screening: mortality rate reduction and screening interval. Edmonton, Alberta, Canada: Alberta Heritage Foundation for Medical Research; June 2000.
162.
Ernster VL, Barclay J. Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: a dilemma. J Natl Cancer Inst Monogr. 1997(22):151–156. [PubMed: 9709292]
163.
Schwartz L M, Woloshin S, Sox H C, Fischhoff B, Welch H G. US women's attitudes to false positive mammography results and detection of ductal carcinoma in situ: cross sectional survey. BMJ. 2000;320(7250):1635–1640. [PMC free article: PMC27408] [PubMed: 10856064]
164.
Welch H G, Fisher E S. Diagnostic testing following screening mammography in the elderly. Journal of the National Cancer Institute. 1998;90(18):1389–1392. [PubMed: 9747869]
165.
Pisano E D, Earp J, Schell M, Vokaty K, Denham A. Screening behavior of women after a false-positive mammogram. Radiology. 1998;208(1):245–249. [PubMed: 9646820]
166.
Lerman C, Track B, Rimer B K, Boyce A, Jepson C, Engstrom P F. Psychological and behavioral implications of abnornal mammograms. Ann Int Med. 1991;114:657–661. [PubMed: 2003712]
167.
Lampic C, Thurfjell E, Bergh J, Sjoden P O. Short- and long-term anxiety and depression in women recalled after breast cancer screening. Eur J Cancer. 2001;37(4):463–469. [PubMed: 11267855]
168.
Meystre-Agustoni G, Paccaud F, Jeannin A, Dubois-Arber F. Anxiety in a cohort of Swiss women participating in a mammographic screening programme. J Med Screen. 2001;8(4):213–219. [PubMed: 11743038]
169.
Ekeberg O, Skjauff H, Karesen R. Screening for breast cancer is associated with a low degree of psychological distress. The Breast. 2001;10(1):20–24. [PubMed: 14965553]
170.
Gram I, Lund E, Slenker S. Quality of life following a false positive mammogram. Br J Cancer. 1990;62(6):1018–1022. [PMC free article: PMC1971570] [PubMed: 2257206]
171.
Ong G, Austoker J, Brett J. Breast screening: adverse psychological consequences one month after placing women on early recall because of a diagnostic uncertainty. A multicentre study. J Med Screen. 1997;4(3):158–168. [PubMed: 9368874]
172.
Holmberg L H, Tabar L, Adami H O, Bergstrom R. Survival in breast cancer diagnosed between mammographic screening examinations. Lancet. 1986;2:27–30. [PubMed: 2873324]
173.
Mattsson A, Leitz W, Rutqvist L E. Radiation risk and mammographic screening of women from 40 to 49 years of age: effect on breast cancer rates and years of life. Br J Cancer. 2000;82(1):220–226. [PMC free article: PMC2363188] [PubMed: 10638993]
174.
Feig SA, Hendrick RE. Radiation risk from screening mammography of women aged 40–49 years. J Natl Cancer Inst Monogr. 1997(22):119–124. [PubMed: 9709287]
175.
Harrison TR. Breast Cancer. In: Fauci AS, ed. Principles of Internal Medicine, 14th ed. New York: McGraw Hill; 1998:564–567.
176.
Swift M, Morrell D, Massey R B, Chase C L. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med. 1991;325(26):1831–1836. [PubMed: 1961222]
177.
US Preventive Services Task Force. Guide to Clinical Preventive Services. Baltimore: Williams and Wilkins; 1989.
178.
Fletcher S W. Why question screening mammography for women in their forties? Radiol Clin North Am. 1995;33(6):1259–1271. [PubMed: 7480669]
179.
Tabar L, Duffy S W, Chen H H. Re: Quantitative interpretation of age-specific mortality reductions from the Swedish Breast Cancer-Screening Trials. Journal of the National Cancer Institute. 1996;88(1):52–55. [PubMed: 8847728]
180.
McPherson K, Steel C M, Dixon J M. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ. 2000;321(7261):624–628. [PMC free article: PMC1118507] [PubMed: 10977847]
181.
Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1973-1997, National Cancer Institute, NIH Pub. No. 00-2789. Bethesda, MD.
182.
Tabar L, Duffy S W, Krusemo U B. Detection method, tumour size and node metastases in breast cancers diagnosed during a trial of breast cancer screening. European Journal of Cancer & Clinical Oncology. 1987;23:959–962. [PubMed: 3311769]
Bookshelf ID: NBK42747

Views

  • PubReader
  • Print View
  • Cite this Page

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...